奥精医疗(688613) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥42,459,701.13, a decrease of 10.35% compared to ¥47,360,874.94 in the same period last year[3]. - Net profit attributable to shareholders was ¥1,041,517.76, down 84.99% from ¥6,938,107.45 year-on-year[3]. - Operating profit for Q1 2025 was a loss of ¥192,414.68, compared to a profit of ¥5,810,383.99 in Q1 2024[16]. - Net profit for Q1 2025 was a loss of ¥192,709.03, down from a net profit of ¥5,389,244.56 in Q1 2024[17]. - Basic and diluted earnings per share were both ¥0.01, reflecting an 80% decrease from ¥0.05 in the same period last year[5]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.01, compared to ¥0.05 in Q1 2024[17]. Cash Flow - The net cash flow from operating activities was -¥15,331,420.11, a significant decline of 633.48% compared to -¥2,090,216.95 in the previous year[3]. - Cash flow from operating activities in Q1 2025 was a net outflow of ¥15,331,420.11, compared to a net outflow of ¥2,090,216.95 in Q1 2024[20]. - Cash flow from investing activities in Q1 2025 was a net outflow of ¥3,232,586.82, significantly down from a net inflow of ¥21,233,193.15 in Q1 2024[21]. - Cash and cash equivalents at the end of Q1 2025 totaled ¥136,433,523.59, down from ¥178,413,682.11 at the end of Q1 2024[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,557,562,292.25, an increase of 1.20% from ¥1,539,163,337.61 at the end of the previous year[5]. - The company's current assets totaled RMB 1,221,187,518.20, compared to RMB 1,196,396,879.83 at the end of 2024, reflecting a growth of approximately 2.1%[12]. - The company's inventory increased significantly to RMB 93,901,737.38 from RMB 54,577,004.67, marking a rise of about 71.9%[12]. - Accounts payable rose to RMB 41,165,811.29 from RMB 12,952,487.19, indicating a substantial increase of approximately 217.5%[14]. - The total liabilities of the company were RMB 134,768,205.79, up from RMB 119,200,213.96, representing an increase of about 13.1%[14]. - The company's equity attributable to shareholders reached RMB 1,406,939,573.16, slightly up from RMB 1,402,874,383.57, showing a marginal increase of 0.2%[14]. - The company's long-term borrowings stood at RMB 41,452,173.33, slightly up from RMB 40,752,173.33, indicating a growth of about 1.7%[14]. - The company's total non-current assets were RMB 336,374,774.05, down from RMB 342,766,457.78, reflecting a decrease of approximately 1.9%[13]. Expenses - Research and development expenses totaled ¥5,146,405.26, representing 12.12% of operating revenue, down from 15.95% in the previous year[5]. - Total operating costs increased to ¥46,643,863.61 in Q1 2025, up 1.8% from ¥45,835,228.75 in Q1 2024[16]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 7,905[9]. - The top shareholder, HU ERIC GANG, holds 7.00% of the shares, with a total of 9,487,066 shares[9]. Other Income - Non-recurring gains and losses amounted to ¥3,383,047.60, with significant contributions from government subsidies and asset disposals[6]. - Other comprehensive income after tax for Q1 2025 was ¥280,869.33, with no comparable figure reported for Q1 2024[17].